I AM ALS Expanding Efforts Into Research, Patient Support

I AM ALS Expanding Efforts Into Research, Patient Support

I AM ALS, a nonprofit dedicated to helping people affected by amyotrophic lateral sclerosis (ALS), is expanding its efforts in scientific research and public policy. The organization’s new Science and Policy program will include three key focuses, according to a press release emailed to ALS News Today.

NIH $1.25M Grant Supports Work Into Nerve Cell Loss in ALS

A Temple University research team received a National Institutes of Health (NIH) grant totaling $1.25 million to explore the molecular underpinnings of neuronal degeneration in amyotrophic lateral sclerosis (ALS) and other diseases. With this five-year grant, the team led by Gareth Thomas, PhD, an associate professor of neural sciences…

Winning the Battle Against Daily Distractions

I love daily routines. For me, having a set of habits and to-do projects waiting to be tackled helps me feel grounded when the world’s events are in turmoil. And more importantly, daily routines keep my mind focused on things other than my ALS. What I don’t love are disruptions,…

Phase 3 Trial of Ultomiris in ALS Patients Stopping for Lack of Efficacy

Alexion Pharmaceuticals is stopping further work on Ultomiris (ravulizumab) — its approved therapy for complement-associated rare blood disorders — as a potential treatment of amyotrophic lateral sclerosis (ALS) based on interim data from the CHAMPION-ALS Phase 3 clinical trial. While top-line results were expected by mid-2022, the study’s independent data…

COMBAT-ALS Trial Still Enrolling in North America

MediciNova is still recruiting adults with early-stage amyotrophic lateral sclerosis (ALS) for the COMBAT-ALS Phase 2b/3 clinical trial evaluating its investigational oral therapy MN-166 (ibudilast). Patients are being enrolled at 19 sites across North America; more information about contacts and locations is available here. “We continue to…

I Hate the Feeling of Knowing What’s Coming

I pleaded. I bargained. I threatened. But it was no use. My dog would not back away from the woods behind the shed, where he had been sprayed by a skunk just two weeks earlier. I was more panicked when he got skunked than I was now. I frantically searched…

Clene Boosts Production Capacity of CNM-Au8

Clene, and its wholly owned subsidiary Clene Nanomedicine, have signed two lease agreements that will more than quadruple the manufacturing capacity of CNM-Au8, their investigational therapy for people with amyotrophic lateral sclerosis (ALS). The first lease is for a 10-year agreement for a 74,210-square-foot building in Elkton, Maryland.

Radicava Prolongs Survival, Small ALS Study Shows

Long-term treatment with Radicava (edaravone) is generally safe and nearly doubles survival time in adults with amyotrophic lateral sclerosis (ALS), according to a small real-life study in Japan. These data add to increasing, but still limited, evidence showing the therapy prolongs the life of ALS patients and…